The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Changing the strategy: early treatment for improved survival in MM
There are multiple ongoing clinical trials looking into early treatment and its positive influence in the multiple myeloma (MM) setting. Irene Ghobrial, MD, from the Dana-Farber Cancer Institute, Boston, MA, USA, mentions a daratumumab trial in patients with low and high risk MGUS, especially with neuropathy or other factors. She explains that these are the type of patients who could benefit significantly from an earlier antibody therapy approach. There are multiple other clinical trials in the high-risk setting, for example, looking at nivolumab in combination with lenalidomide and dexamethasone (len/dex). We are excited to see the first immune checkpoint inhibitor in high risk smoldering disease. Trying to use our immune system to harness its prevention against progression would be an exciting time. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
